Search bioRxiv⌕ Search

Biology subjects

Snyder, S. A.

Publications and source records attributed to Snyder, S. A..

2 recordsLinked to original sources

Restriction of innate Tγδ17 cell plasticity by an AP-1 regulatory axis

IL-17-producing {gamma}{delta} T (T{gamma}{delta}17) cells are innate-like mediators of intestinal barrier immunity. While Th17 cell and ILC3 plasticity have been extensively studied, the mechanisms governing T{gamma}{delta}17 cell effector flexibility remain undefined. Here, we combined type 3 fate-mapping with single cell ATAC/RNA-seq multiome profiling to define the cellular features and regulatory networks underlying T{gamma}{delta}17 cell plasticity. During homeostasis, T{gamma}{delta}17 cell effector identity was stable across tissues, including for intestinal T-bet+ T{gamma}{delta}17 cells that restrained IFN{gamma} production. However, S. typhimurium infection induced intestinal V{gamma}6+ T{gamma}{delta}17 cell conversion into type 1 effectors, with loss of IL-17A production and partial ROR{gamma}t downregulation. Multiome analysis revealed a trajectory along V{gamma}6+ T{gamma}{delta}17 effector conversion, with TIM-3 marking ex-T{gamma}{delta}17 cells with enhanced type 1 functionality. Lastly, we characterized and validated a critical AP-1 regulatory axis centered around JunB and Fosl2 that controls V{gamma}6+ T{gamma}{delta}17 cell plasticity by stabilizing type 3 identity and restricting type 1 effector conversion.

immunology↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

The number of new cases world-wide for the COVID-19 disease is increasing dramatically, while efforts to contain Severe Acute Respiratory Syndrome Coronavirus 2 is producing varied results in different countries. There are three key SARS-CoV-2 enzymes potentially targetable with antivirals: papain-like protease (PLpro), main protease (Mpro), and RNA-dependent RNA polymerase. Of these, PLpro is an especially attractive target because it plays an essential role in several viral replication processes, including cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex (RTC), and disruption of host viral response machinery to facilitate viral proliferation and replication. Moreover, this enzyme is conserved across different coronaviruses and promising inhibitors have already been discovered for its SARS-CoV variant. Here we report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the enzyme from SARS-CoV-2 in both wild-type and mutant forms. These efforts include the first structures of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors, determined at 1.60-2.70 Angstroms. This collection of structures provides fundamental molecular and mechanistic insight to PLpro, and critically, illustrates details for inhibitors recognition and interactions. All presented compounds inhibit the peptidase activity of PLpro in vitro, and some molecules block SARS-CoV-2 replication in cell culture assays. These collated findings will accelerate further structure-based drug design efforts targeting PLpro, with the ultimate goal of identifying high-affinity inhibitors of clinical value for SARS-CoV-2.

molecular biology↗